StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Farxiga / Forxiga (dapagliflozin) by Year

Farxiga / Forxiga (dapagliflozin) — Established RoW YoY actual (%) (%)

AstraZeneca Farxiga / Forxiga (dapagliflozin): -3.0% in FY2025, down 3.0 pts from a year earlier.

Latest, FY2025
-3.0%
Period ended Dec 31, 2025
Change on a year earlier
-3.0 pts
0.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| Farxiga | 8,400 | 10 | 9 | 1,730 | (1) | 3,324 | 17 | 18 | 2,941 | 12 | 8 | 405 | (3) | (3)”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFarxiga / Forxiga (dapagliflozin) — Established RoW YoY actual (%) (%)Year on yearSource
FY2025Dec 31, 2025-3.0%-3.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
FY2024Dec 31, 20240.0%-21.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
FY2023Dec 31, 202321.0%-11.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
FY2022Dec 31, 202232.0%-2.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
FY2021Dec 31, 202134.0%+13.0 ptsForm 6-K FY2021Q4 Earnings Release ↗
FY2020Dec 31, 202021.0%–Form 6-K FY2020Q4 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) (%), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-farxiga-erow-act-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?